Hos patienter med ankyloserende spondylitis blev der påvist anti- adalimumab antistoffer hos 17/ 204 patienter (8, 3%) behandlet med adalimumab.
In patients with ankylosing spondylitis anti-adalimumab antibodies were identified in 17/ 204 subjects (8.3%) treated with adalimumab.